Genetic variants of severe acute respiratory syndrome coronavirus (SARS-CoV-2) have
been globally surging and devastating many countries around the world. There are at least …

The SARS-CoV-2 genome has undergone several mutations since the beginning of the
pandemic in December 2019. A number of these mutants were associated with higher …

Following severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine,,
European health authorities recommended that patients under the age of 55 years who …

In humans, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is highly
infective, often causes severe acute and/or long-term illness, and elicits a high rate of …

Since its emersion, coronavirus disease 2019 (COVID‐19) has been a significant global
dilemma. Several mutations in the severe acute respiratory virus (SARS‐Co‐2) genome has …

Vaccines are proving to be highly effective in controlling hospitalization and deaths
associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

Background Schools were closed extensively in 2020–21 to counter SARS-CoV-2 spread,
impacting students' education and wellbeing. With highly contagious variants expanding in …

Several SARS‐CoV‐2 variants have emerged since the pandemic, bringing about a
renewed threat to the public. Delta variant (B. 1.617. 2) was first detected in October 2020 in …

Introduction: Novel coronavirus (COVID-19) and tuberculosis (TB) are the newest and one of
the oldest global threats, respectively. In the COVID-19 era, due to the health system's focus …

Introduction Coronavirus disease 2019 resulted in a 30% mortality rate in patients with
thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute …